Latest news

The biopharmaceutical company, aptaTargets, reaches an agreement with Merck for the clinical development and commercialisation of the drug, ApTOLL
RCD news

RCD has advised the biopharmaceutical company, aptaTargets, on an agreement with the German multinational pharmaceutical company Merck KGaA for the clinical development and commercialisation of ApTOLL, a Toll-like receptor 4 (TLR4) antagonist being developed for acute ischaemic stroke